Novo Holdings invests in proteomics technology company, Evosep
COPENHAGEN, Denmark, Jan. 9, 2023 /PRNewswire/ -- Novo Holdings, a leading international life science investor, today announced a $40m investment in Evosep, the bioscience company leading the standardisation of proteomics for clinical use.
- COPENHAGEN, Denmark, Jan. 9, 2023 /PRNewswire/ -- Novo Holdings, a leading international life science investor, today announced a $40m investment in Evosep, the bioscience company leading the standardisation of proteomics for clinical use.
- The proceeds from the investment by Novo Holdings will be used to advance clinical applications of proteomics enabled by Evosep's standardised liquid chromatography platform.
- "We are delighted to have Novo Holdings A/S as a new shareholder in Evosep.
- We are confident that Evosep, with their advanced technology, will create significant positive change in the healthcare sector."